Welcome back to Healthy Innovations! 👋
Today is World Health Day, and this year’s theme – “Together for Health. Stand with Science” – feels especially fitting. This week, we’re looking at what happens when scientists across seven countries pool their data, share research openly, and refuse to let a disease go untreated simply because it isn’t profitable.
The result? Three pills, one dose, and a real shot at eradicating one of Africa's oldest killers.
Let's dive in!
World Health Day 2026 campaign
Somewhere in the Democratic Republic of Congo (DRC), a patient is about to swallow three pills, once, and be cured of a disease that has killed people across Africa for centuries.
That result took decades of shared science to reach.
In February 2026, the European Medicines Agency issued a positive opinion for acoziborole – a single-dose oral treatment for sleeping sickness.
A Science article called the result “truly spectacular.” Veteran researchers who have spent their careers fighting the disease are now talking openly about “elimination.” For patients in some of the most remote communities in sub‑Saharan Africa, that could soon mean a cure with no hospital stay, no IV, and no follow‑up visits.
🪰 What is sleeping sickness?
Sleeping sickness – known clinically as human African trypanosomiasis (HAT) – is caused by a parasite spread through the bite of the tsetse fly. It affects people across sub-Saharan Africa, with the DRC accounting for more than 70% of all reported cases.
Without treatment, it is fatal.
As the parasite reaches the brain, it triggers a range of neurological symptoms:
Severe disruption to sleep cycles – hence the name
Confusion, personality changes, and in some cases aggression or psychosis
Coma and death if left untreated
"This is a disease that looks like spirits attacking you, alcoholism, PTSD, or malaria," notes one researcher – symptoms that don't always prompt people to seek care, even when treatment is available.
A history of difficult treatments
For almost 60 years, the main drug for sleeping sickness was melarsoprol – a derivative of arsenic developed in the 1940s.
It killed nearly one in every 20 patients who received it.
Progress came slowly:
2009: NECT, a combination of IV infusions and pills, replaced melarsoprol. Effective, but required hospital admission and specialist staff
2018/2019: Fexinidazole became the first all-oral treatment – but required ten days of daily doses, came with significant side effects, and only worked for mild and intermediate cases
The staging problem: Distinguishing mild from severe cases required a lumbar puncture – a needle inserted into the spinal cord. Painful, invasive, and impossible in many remote field settings.
Many people who had watched relatives suffer through earlier treatments simply stopped coming forward. In addition, as regimens are so complex, care is often limited to people with parasites confirmed in the blood, but that confirmation depends on microscopes and trained technicians, and it still misses an estimated 15% of infections.
One dose changes the calculation
Acoziborole, developed by DNDi (Drugs for Neglected Diseases initiative) and Sanofi, clears most of those hurdles at once.
Single dose: Three tablets taken together, once. No ten-day course. No daily monitoring
Both stages: It treats mild and severe cases, eliminating the need for a lumbar puncture to stage the disease
Field-friendly: The pills can be transported easily and administered at village level, without hospitalisation
Success rate: A phase 2/3 trial in 208 patients in Guinea and the DRC, published in The Lancet Infectious Diseases online in 2022, showed success rates of up to 96% at 18 months across both disease stages
Side effects: The most common was a mild to moderate headache
Sanofi has pledged to donate the medicine through its philanthropic arm, Foundation S, for free provision in endemic countries via WHO.
Image source: DNDi
Science in the field – what it actually took
The clinical trials for acoziborole were run in remote, under-resourced settings with no existing research infrastructure. Teams had to install electricity, running water, and internet connections before a single patient could be enrolled. Health workers were trained from the ground up.
And then patients who had avoided treatment for years – sometimes after watching relatives endure earlier drugs – began to show up.
The development of acoziborole is a victory for Africa-led science, made possible thanks to African doctors and researchers who conducted cutting-edge pharmaceutical research in some of the most remote and difficult-to-reach areas on the continent.
Why this drug exists at all
Acoziborole did not emerge from a standard commercial pipeline. Sleeping sickness primarily affects people in low-income countries – there is little profit incentive for traditional pharma to invest.
DNDi was founded in 2003 specifically to fill that gap, by seven institutions including Médecins Sans Frontières, WHO, Institut Pasteur, and medical research bodies from India, Kenya, Malaysia, and Brazil. Its model: share data openly, pool expertise across borders, and develop drugs as public goods.
The compound that became acoziborole was first identified in by a small California biotech, Anacor Pharmaceuticals, later acquired by Pfizer. Scientists then modified it to reach the brain more effectively, ran Phase 1 safety trials across France, the UK, and Malaysia, and conducted the pivotal trial in Guinea and the DRC.
It is a genuinely global story – and one that would not have happened under a conventional closed, competitive research model.
Gap to watch: Sleeping sickness elimination by 2030 is a WHO target – and acoziborole makes it plausible. But global health aid budgets are under pressure in 2026. Researchers are clear that sustaining surveillance and access, even as case numbers fall, will be critical. As infections become rarer, both health workers and communities become less likely to recognise them.
What comes next
The science keeps moving. Researchers are testing whether acoziborole could be given to anyone who tests positive on a simple antibody test – removing the need for microscopy entirely and potentially catching the 15% of cases currently missed. Results from the ACOZI-Kids trial, testing the drug in children aged one to fourteen, are expected in late 2026.
If the antibody trial succeeds, a disease that once required hospital admission, invasive procedures, and weeks of treatment could be diagnosed and cured in a single field visit. That is what decades of open, collaborative science can produce – when it is properly funded and sustained.
Innovation highlights
🥽 AR games, real gains. Prosthetic rejection is a real problem. Many upper limb amputees find it easier to rely on their uninjured arm simply because they never got enough training. Researchers tested whether an augmented reality game could change that. Using a Microsoft HoloLens2 headset, participants stacked holographic cups while wearing a prosthesis. Those in the AR group were "significantly more efficient" at functional tasks than the control group – and reported feeling genuinely engaged throughout.
💧 Sweat's secret antiviral weapon. Your body may already be fighting the flu before you even feel sick. Researchers found that dermcidin, a peptide produced naturally in sweat, blocks influenza by binding to hemagglutinin, the protein the virus needs to enter cells. People who stayed symptom-free had baseline dermcidin levels up to six times higher than those who got sick. The finding could pave the way for a new class of broad-spectrum antivirals.
🦿 Smart joints, smarter care. Researchers are a step closer to knee implants that monitor themselves. Nearly 800,000 knee replacements happen annually in the US, yet one in five patients experiences loosening or joint imbalance – often caught too late. The team's solution uses piezoelectric and triboelectric transducers to convert knee movement into power for embedded sensors, creating a self-powered load monitor.
Cool tool
🏥 Cera, Europe’s largest healthtech, has developed an app that has become one of the NHS's most relied-on digital tools. During home visits, carers log vital signs – blood pressure, heart rate, temperature, sleep, mood – directly into the app, replacing paper notes with real-time digital records. That standardized data feeds AI algorithms that can predict falls and infections up to 7 days in advance, with 97% accuracy.
Since 2023, that early warning capability has reduced hospitalizations by up to 70%. Families get live updates through a companion app, so they're never left wondering. Now running across two-thirds of NHS systems and monitoring over 2 million patients monthly, Cera keeps vulnerable people at home, safer, for longer.
Image source: mobihealthnews
Weird and wonderful
☕ Coffee's got competition, finally. Forget your double espresso. A new drug called solriamfetol may soon give early-morning shift workers a real fighting chance against their 3 am alarm. Published in the peer-reviewed journal NEJM Evidence, a randomized, double-blind, placebo-controlled trial of nearly 100 participants found those who took the drug were significantly less sleepy during shifts starting between 3 and 7 am.
Solriamfetol works by blocking the reuptake of dopamine and norepinephrine, basically nudging the brain's own alertness system awake. Researchers say Shift Work Disorder traps people in a "double burden" – sleepy at work, unable to sleep at home. Left unchecked, it can progress to CVD, GI issues, or even cancer.
Image created using Canva AI
Thank you for reading the Healthy Innovations newsletter!
Keep an eye out for next week’s issue, where I will highlight the healthcare innovations you need to know about.
Have a great week!
Alison ✨
P.S. If you enjoyed reading the Healthy Innovations newsletter, please subscribe so I know the content is valuable to you!
